Salivary BPIFA proteins are altered in patients undergoing hematopoietic cell transplantation

Autor(es)

Innocentini, Lara Maria Alencar Ramos ; Silva, Andreia Aparecida ; Carvalho, Marco Antonio ; Coletta, Ricardo D. ; Correa, Maria Elvira Pizzigatti ; Bingle, Lynne ; Bingle, Colin D. ; Vargas, Pablo Agustin ; Lopes, Marcio Ajudarte

• Tipo de documento: Artigo Científico
• Fonte: ORAL DISEASES; v. 28, n. 4, p. 10-pg., 2021-04-05.

Resumo

Objective The aim of this study was to evaluate the expression of BPIFA proteins in the saliva and salivary glands of hematopoietic cell transplant (HCT) patients. Material and Methods This longitudinal study included patients who had undergone autologous HCT (auto-HCT) and allogeneic HCT (allo-HCT), and unstimulated saliva was collected at three time points, with a fourth collection at oral chronic graft-versus-host disease (cGVHD) onset. BPIFA expression was analysed by Western blotting in saliva and immunostaining in the minor salivary glands of cGVHD patients. Results Auto-HCT patients showed increased levels of BPIFA1 (p = .021) and BPIFA2 at D+7 (p = .040), whereas allo-HCT group demonstrated decreased expression of BPIFA2 at D+8 (p = .002) and at D+80 (p = .001) and a significant association between BPIFA2 low levels and hyposalivation was observed (p = .02). BPIFA2 was significantly lower in the cGVHD patients when compared to baseline (p = .04). Conclusions The results of this study show distinct pattern of expression of BPIF proteins in both auto-HCT and allo-HCT recipients with decreased levels of BPIFA2 during hyposalivation and cGVHD. Further studies are necessary to elucidate these proteins mechanisms and their clinical implications in these groups of patients. (AU)

• Processo FAPESP: 11/07853-3 - Avaliação da expressão de proteínas da família plunc em pacientes com DECH, TCTH, câncer de cabeça e pescoço
• Beneficiário: Pablo Agustin Vargas
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 11/00711-9 - Estudo clínico laboratorial de pacientes que receberão quimioterapia
• Beneficiário: Lara Maria Alencar Ramos Innocentini
• Modalidade de apoio: Bolsas no Brasil - Doutorado